A New Mechanism for an Old Drug: How Acarbose Protects the Kidneys in Diabetes
A study published in *Science Translational Medicine* reveals a novel pharmacodynamic mechanism for the common diabetes drug acarbose. Researchers found that acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy by activating the deubiquitinating enzyme USP46. This discovery moves beyond the drug’s known mechanism of alpha-glucosidase inhibition in the gut, identifying a direct, protective effect on kidney cells that is central to preventing a major diabetic complication. The research provides a clear example of drug repurposing based on newly understood pathways of enzyme activation and cellular protection.
Study Significance: For pharmacologists, this work underscores the importance of investigating secondary mechanisms of action for established therapeutics, which can reveal new therapeutic windows and applications. Understanding that acarbose’s efficacy in diabetic nephropathy involves USP46 activation opens avenues for developing more targeted enzyme modulators or optimizing therapeutic drug monitoring for kidney protection. This shifts the strategic view of the drug from a purely metabolic agent to a potential renoprotective one, influencing future clinical trial design and personalized medicine approaches for diabetic patients.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
